Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $72.7 million.

  • Silence Therapeutics' Total Liabilities fell 6551.22% to $72.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.7 million, marking a year-over-year decrease of 6551.22%. This contributed to the annual value of $68.6 million for FY2024, which is 2959.62% down from last year.
  • As of Q3 2025, Silence Therapeutics' Total Liabilities stood at $72.7 million, which was down 6551.22% from $71.1 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Total Liabilities ranged from a high of $237.7 million in Q1 2024 and a low of -$22.6 million during Q3 2021
  • Its 5-year average for Total Liabilities is $113.7 million, with a median of $108.4 million in 2021.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 72002.58% in 2022, then tumbled by 6947.77% in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Total Liabilities stood at $118.2 million in 2021, then fell by 15.21% to $100.2 million in 2022, then increased by 8.85% to $109.1 million in 2023, then tumbled by 37.1% to $68.6 million in 2024, then increased by 6.0% to $72.7 million in 2025.
  • Its Total Liabilities stands at $72.7 million for Q3 2025, versus $71.1 million for Q2 2025 and $72.6 million for Q1 2025.